IL299123B2 - Quinoxaline derivatives as anticancer drugs - Google Patents
Quinoxaline derivatives as anticancer drugsInfo
- Publication number
- IL299123B2 IL299123B2 IL299123A IL29912322A IL299123B2 IL 299123 B2 IL299123 B2 IL 299123B2 IL 299123 A IL299123 A IL 299123A IL 29912322 A IL29912322 A IL 29912322A IL 299123 B2 IL299123 B2 IL 299123B2
- Authority
- IL
- Israel
- Prior art keywords
- cancer drugs
- quinoxaline derivatives
- quinoxaline
- derivatives
- drugs
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063044095P | 2020-06-25 | 2020-06-25 | |
| US202063120351P | 2020-12-02 | 2020-12-02 | |
| PCT/EP2021/067304 WO2021260092A1 (en) | 2020-06-25 | 2021-06-24 | Quinoxaline derivatives as anti-cancer drugs |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL299123A IL299123A (en) | 2023-02-01 |
| IL299123B1 IL299123B1 (en) | 2025-12-01 |
| IL299123B2 true IL299123B2 (en) | 2026-04-01 |
Family
ID=76662494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL299123A IL299123B2 (en) | 2020-06-25 | 2021-06-24 | Quinoxaline derivatives as anticancer drugs |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US11795158B2 (https=) |
| EP (1) | EP4172152A1 (https=) |
| JP (1) | JP7769650B2 (https=) |
| KR (1) | KR20230026450A (https=) |
| CN (2) | CN115768760B (https=) |
| AU (1) | AU2021295423B2 (https=) |
| BR (1) | BR112022025435A2 (https=) |
| CA (1) | CA3186996A1 (https=) |
| CL (1) | CL2022003711A1 (https=) |
| CO (1) | CO2023000186A2 (https=) |
| CR (1) | CR20230024A (https=) |
| DO (1) | DOP2022000288A (https=) |
| EC (1) | ECSP23005059A (https=) |
| IL (1) | IL299123B2 (https=) |
| MX (1) | MX2022015435A (https=) |
| PE (1) | PE20231081A1 (https=) |
| SA (1) | SA522441701B1 (https=) |
| TW (1) | TW202218664A (https=) |
| UA (1) | UA130043C2 (https=) |
| UY (1) | UY39296A (https=) |
| WO (1) | WO2021260092A1 (https=) |
| ZA (1) | ZA202300924B (https=) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022000711A (es) | 2019-07-19 | 2022-02-23 | Astrazeneca Ab | Inhibidores de parp1. |
| US11795158B2 (en) * | 2020-06-25 | 2023-10-24 | Astrazeneca Ab | Chemical compounds |
| US12280049B2 (en) * | 2020-08-04 | 2025-04-22 | Astrazeneca Ab | Methods of delaying pain progression and treating prostate cancer |
| TW202309025A (zh) | 2021-04-19 | 2023-03-01 | 美商辛瑟拉股份有限公司 | Parp1抑制劑及其用途 |
| TW202304911A (zh) * | 2021-04-23 | 2023-02-01 | 大陸商南京明德新藥研發有限公司 | 吡啶醯胺類化合物 |
| EP4349836A4 (en) | 2021-05-24 | 2024-10-30 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, ITS PREPARATION METHOD AND ITS APPLICATION IN DRUGS |
| JP2024522736A (ja) * | 2021-06-16 | 2024-06-21 | リペア セラピューティクス インコーポレイテッド | がん治療のためのｐａｒｐ阻害剤と組み合わせたａｔｒ阻害剤の使用 |
| US20240366584A1 (en) | 2021-06-21 | 2024-11-07 | Tesaro, Inc. | Combination treatment of cancer with a parp inhibitor and a lipophilic statin |
| AU2022334408A1 (en) | 2021-08-27 | 2024-02-15 | Impact Therapeutics (Shanghai), Inc. | Substituted tricyclic compounds as parp inhibitors and use thereof |
| WO2023046034A1 (zh) * | 2021-09-22 | 2023-03-30 | 明慧医药（杭州）有限公司 | 一种含氮杂环化合物、其制备方法、其中间体及其应用 |
| WO2023046158A1 (zh) * | 2021-09-26 | 2023-03-30 | 张文燕 | 氮杂喹啉酮类化合物及其医药用途 |
| WO2023046149A1 (zh) * | 2021-09-26 | 2023-03-30 | 张文燕 | 喹喔啉类化合物及其医药用途 |
| US20240391937A1 (en) * | 2021-09-30 | 2024-11-28 | Xizang Haisco Pharmaceutical Co., Ltd. | Bicyclic derivative parp inhibitor and use thereof |
| WO2023051716A1 (zh) * | 2021-09-30 | 2023-04-06 | 海思科医药集团股份有限公司 | 杂芳基衍生物parp抑制剂及其用途 |
| US20230159525A1 (en) | 2021-10-01 | 2023-05-25 | Xinthera, Inc. | Azetidine and pyrrolidine parp1 inhibitors and uses thereof |
| JP7762306B2 (ja) | 2021-11-19 | 2025-10-29 | 康百達（四川）生物医薬科技有限公司 | 選択的ｐａｒｐ１阻害剤およびその用途 |
| IL313661A (en) * | 2021-12-21 | 2024-08-01 | Astrazeneca Ab | Methods of treating brain tumours and neuroblastomas |
| WO2023134647A1 (zh) * | 2022-01-13 | 2023-07-20 | 优领医药科技(香港)有限公司 | 含哌嗪并环类衍生物、其药学上可接受的盐及其制备方法和应用 |
| WO2023138541A1 (zh) * | 2022-01-20 | 2023-07-27 | 微境生物医药科技(上海)有限公司 | 吡啶酰胺类parp抑制剂、及其制备方法和医药用途 |
| AU2023209820B2 (en) | 2022-01-21 | 2024-10-10 | Xinthera, Inc. | Parp1 inhibitors and uses thereof |
| US20260098024A1 (en) * | 2022-01-27 | 2026-04-09 | Xinthera, Inc. | Parp1 inhibitors and uses thereof |
| WO2023146960A1 (en) * | 2022-01-28 | 2023-08-03 | Xinthera, Inc. | Parp1 inhibitors and uses thereof |
| CN116693501B (zh) * | 2022-02-10 | 2025-12-19 | 康百达（四川）生物医药科技有限公司 | 一种喹唑啉酮衍生物及其在医药上的应用 |
| KR20240161147A (ko) | 2022-03-14 | 2024-11-12 | 슬랩 파마슈티컬스 엘엘씨 | 다중 사이클릭 화합물 |
| WO2023201338A1 (en) | 2022-04-15 | 2023-10-19 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a parp inhibitor |
| FI4497438T3 (fi) | 2022-04-28 | 2025-10-20 | Xinthera Inc | Trisyklisiä parp1:n estäjiä ja niiden käyttötapoja |
| WO2023207284A1 (en) * | 2022-04-28 | 2023-11-02 | Ningbo Newbay Technology Development Co., Ltd | Piperazine derivatives as parp1 inhibitiors |
| CN119110801A (zh) * | 2022-05-07 | 2024-12-10 | 南京明德新药研发有限公司 | 选择性抑制parp1的氟代喹喔啉酮衍生物 |
| CN119255995A (zh) | 2022-05-25 | 2025-01-03 | 西藏海思科制药有限公司 | 双环衍生物parp抑制剂及其用途 |
| US20250346573A1 (en) * | 2022-06-02 | 2025-11-13 | Chengdu Easton Biopharmaceuticals Co., Ltd. | Azaquinolinone derivative, preparation method therefor and use thereof |
| IL317573A (en) | 2022-06-15 | 2025-02-01 | Astrazeneca Ab | Combination therapy for cancer treatment |
| CN115919859B (zh) * | 2022-07-14 | 2024-01-05 | 四川海思科制药有限公司 | 一种杂芳基衍生物的药物组合物及其在医药上的应用 |
| CN117658983A (zh) * | 2022-09-01 | 2024-03-08 | 浙江文达医药科技有限公司 | 选择性parp1抑制剂 |
| TW202416977A (zh) * | 2022-09-30 | 2024-05-01 | 大陸商中國醫藥研究開發中心有限公司 | 含氮雜環類化合物及其醫藥用途 |
| US20240174669A1 (en) * | 2022-10-06 | 2024-05-30 | Xinthera, Inc. | Crystalline forms of a parp1 inhibitor |
| WO2024083218A1 (zh) * | 2022-10-20 | 2024-04-25 | 成都赜灵生物医药科技有限公司 | 取代四氢吡啶类化合物及其用途 |
| CN120035596A (zh) | 2022-11-23 | 2025-05-23 | 江苏恒瑞医药股份有限公司 | 一种含氮杂环类化合物的可药用盐、晶型及制备方法 |
| IL321260A (en) | 2022-12-06 | 2025-08-01 | Astrazeneca Ab | Polq inhibitors |
| EP4729514A1 (en) | 2023-06-14 | 2026-04-22 | Haisco Pharmaceutical Group Co., Ltd. | Bicyclic derivative parp inhibitor and use thereof |
| WO2025067417A1 (zh) | 2023-09-28 | 2025-04-03 | 成都赜灵生物医药科技有限公司 | 并内酰胺环类化合物及其用途 |
| WO2025092973A1 (zh) * | 2023-11-03 | 2025-05-08 | 成都赜灵生物医药科技有限公司 | Parp1靶向化合物及其用途 |
| TW202535479A (zh) | 2023-12-05 | 2025-09-16 | 英商阿斯特捷利康英國股份有限公司 | 抗體藥物結合物與血腦屏障穿透性ｐａｒｐ１選擇性抑制劑之組合 |
| CN120398887A (zh) * | 2024-01-31 | 2025-08-01 | 西藏海思科制药有限公司 | 一种双环衍生物parp抑制剂的晶型及其制备方法和应用 |
| KR20250128449A (ko) | 2024-02-20 | 2025-08-28 | 주식회사 종근당 | Parp1 억제제로서의 화합물 및 이를 포함하는 약학적 조성물 |
| WO2025248117A1 (en) | 2024-05-31 | 2025-12-04 | Astrazeneca Ab | 6-aminopurine derivatives useful as polq inhibitors |
| TW202547478A (zh) | 2024-05-31 | 2025-12-16 | 瑞典商阿斯特捷利康公司 | Ｐｏｌｑ抑制劑 |
| KR20260019426A (ko) | 2024-08-01 | 2026-02-10 | 주식회사 종근당 | Parp1 억제제로서의 화합물 및 이를 포함하는 약학적 조성물 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0699754T3 (da) | 1994-08-12 | 2001-02-26 | Myriad Genetics Inc | Fremgangsmåde til diagnosticering af prædisposition for bryst- og ovariecancer |
| EP0705903B2 (en) | 1994-08-12 | 2009-08-12 | The University of Utah Research Foundation | Mutations in the 17q-linked breast and ovarian cancer susceptibility gene |
| WO2003007959A1 (en) * | 2001-07-16 | 2003-01-30 | Fujisawa Pharmaceutical Co., Ltd. | Quinoxaline derivatives which have parp inhibitory action |
| BRPI0408284B8 (pt) | 2003-03-12 | 2021-05-25 | Kudos Pharm Ltd | compostos derivados de ftalazinona, seu uso e composição farmacêutica compreendendo os mesmos |
| JP2010507387A (ja) | 2006-10-25 | 2010-03-11 | クアーク・ファーマスーティカルス、インコーポレイテッド | 新規のｓｉＲＮＡおよびその使用方法 |
| US8048892B2 (en) | 2006-12-18 | 2011-11-01 | Amgen Inc. | Azaquinolone based compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof |
| JP2009196973A (ja) * | 2007-09-26 | 2009-09-03 | Santen Pharmaceut Co Ltd | キナゾリノン誘導体又はキノキサリン誘導体を有効成分として含有する後眼部疾患の予防又は治療剤 |
| US8404713B2 (en) * | 2007-10-26 | 2013-03-26 | Janssen Pharmaceutica Nv | Quinolinone derivatives as PARP inhibitors |
| KR101779137B1 (ko) | 2009-01-23 | 2017-09-18 | 다케다 야쿠힌 고교 가부시키가이샤 | 폴리(ａｄｐ-리보스)폴리머라제(ｐａｒｐ) 억제제 |
| WO2014045101A1 (en) * | 2012-09-21 | 2014-03-27 | Cellzome Gmbh | Tetrazolo quinoxaline derivatives as tankyrase inhibitors |
| HK1211033A1 (en) * | 2012-12-20 | 2016-05-13 | Bayer Pharma Aktiengesellschaft | Bet-protein-inhibiting dihydroquinoxalinones |
| EP2972381A2 (en) | 2013-03-14 | 2016-01-20 | Galapagos NV | Molecular targets and compounds, and methods to identify the same, useful in the treatment of diseases associated with epithelial mesenchymal transition |
| TWI772856B (zh) | 2013-07-19 | 2022-08-01 | 美商百健Ｍａ公司 | 用於調節τ蛋白表現之組合物 |
| PH12017502228B1 (en) * | 2015-06-09 | 2022-08-03 | Onconic Therapeutics Inc | Tricyclic derivative compound, method for preparing same, and pharmaceutical composition comprising same |
| MX2022000711A (es) | 2019-07-19 | 2022-02-23 | Astrazeneca Ab | Inhibidores de parp1. |
| US11795158B2 (en) * | 2020-06-25 | 2023-10-24 | Astrazeneca Ab | Chemical compounds |
-
2021
- 2021-06-22 US US17/354,322 patent/US11795158B2/en active Active
- 2021-06-24 CA CA3186996A patent/CA3186996A1/en active Pending
- 2021-06-24 UA UAA202300158A patent/UA130043C2/uk unknown
- 2021-06-24 EP EP21735690.6A patent/EP4172152A1/en active Pending
- 2021-06-24 CN CN202180043057.8A patent/CN115768760B/zh active Active
- 2021-06-24 JP JP2022579869A patent/JP7769650B2/ja active Active
- 2021-06-24 IL IL299123A patent/IL299123B2/en unknown
- 2021-06-24 WO PCT/EP2021/067304 patent/WO2021260092A1/en not_active Ceased
- 2021-06-24 MX MX2022015435A patent/MX2022015435A/es unknown
- 2021-06-24 KR KR1020237001972A patent/KR20230026450A/ko active Pending
- 2021-06-24 CN CN202610271871.XA patent/CN121873040A/zh active Pending
- 2021-06-24 BR BR112022025435A patent/BR112022025435A2/pt unknown
- 2021-06-24 CR CR20230024A patent/CR20230024A/es unknown
- 2021-06-24 AU AU2021295423A patent/AU2021295423B2/en active Active
- 2021-06-24 PE PE2022002989A patent/PE20231081A1/es unknown
- 2021-06-25 TW TW110123282A patent/TW202218664A/zh unknown
- 2021-06-25 UY UY0001039296A patent/UY39296A/es unknown
-
2022
- 2022-12-11 SA SA522441701A patent/SA522441701B1/ar unknown
- 2022-12-14 DO DO2022000288A patent/DOP2022000288A/es unknown
- 2022-12-22 CL CL2022003711A patent/CL2022003711A1/es unknown
-
2023
- 2023-01-10 CO CONC2023/0000186A patent/CO2023000186A2/es unknown
- 2023-01-20 ZA ZA2023/00924A patent/ZA202300924B/en unknown
- 2023-01-23 EC ECSENADI20235059A patent/ECSP23005059A/es unknown
- 2023-09-14 US US18/467,185 patent/US12421208B2/en active Active
-
2025
- 2025-08-12 US US19/297,723 patent/US20250368615A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023532257A (ja) | 2023-07-27 |
| JP7769650B2 (ja) | 2025-11-13 |
| US12421208B2 (en) | 2025-09-23 |
| US20240010631A1 (en) | 2024-01-11 |
| UA130043C2 (uk) | 2025-10-22 |
| IL299123B1 (en) | 2025-12-01 |
| ECSP23005059A (es) | 2023-02-28 |
| CN115768760A (zh) | 2023-03-07 |
| ZA202300924B (en) | 2024-09-25 |
| IL299123A (en) | 2023-02-01 |
| US20220009901A1 (en) | 2022-01-13 |
| CN115768760B (zh) | 2026-03-27 |
| SA522441701B1 (ar) | 2024-08-11 |
| UY39296A (es) | 2021-12-31 |
| CA3186996A1 (en) | 2021-12-30 |
| US11795158B2 (en) | 2023-10-24 |
| US20250368615A1 (en) | 2025-12-04 |
| WO2021260092A1 (en) | 2021-12-30 |
| EP4172152A1 (en) | 2023-05-03 |
| CO2023000186A2 (es) | 2023-04-17 |
| CR20230024A (es) | 2023-03-01 |
| BR112022025435A2 (pt) | 2023-01-24 |
| DOP2022000288A (es) | 2023-01-15 |
| PE20231081A1 (es) | 2023-07-17 |
| CN121873040A (zh) | 2026-04-17 |
| AU2021295423B2 (en) | 2024-05-02 |
| CL2022003711A1 (es) | 2023-06-23 |
| AU2021295423A1 (en) | 2023-02-16 |
| KR20230026450A (ko) | 2023-02-24 |
| MX2022015435A (es) | 2023-02-09 |
| TW202218664A (zh) | 2022-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL299123B2 (en) | Quinoxaline derivatives as anticancer drugs | |
| IL307911B1 (en) | Heterocyclic derivatives, medicinal preparations containing them and their use as medicines. | |
| ZA202007143B (en) | Pyridone derivative, composition thereof and application thereof as anti-influenza drug | |
| LT4094804T (lt) | Arilamido dariniai, pasižymintys priešnavikiniu aktyvumu | |
| EP3269715A4 (en) | Substituted 2-hydrogen-pyrazole derivative serving as anticancer drug | |
| MX2017010102A (es) | Conjugado farmaco citotoxico-ligando, metodo de preparacion del mismo, y sus aplicaciones. | |
| MX2016009332A (es) | Conjugado de farmaco citotoxico-ligando, metodo de preparacion del mismo y uso del mismo. | |
| IL287571A (en) | Stabilization of camptothecin pharmaceutical preparations | |
| EP3378482A4 (en) | FORMULATION FOR ADMINISTRATION OF ANTIMORALS | |
| EP3159338A4 (en) | Pyrimidine-2,4-diamine derivative and anticancer pharmaceutical composition comprising same as effective ingredient | |
| EP3082817A4 (en) | Compositions for drug administration | |
| IL272638A (en) | History of quinoxaline, their preparation and pharmaceutical preparations containing them | |
| AU2018297348A1 (en) | Compositions for parenteral administration of therapeutic agents | |
| IL236057B (en) | History of 4,2,1-triazine-6-carboxamide and pharmaceutical preparations containing them | |
| EP3290038A4 (en) | Agent for alleviating adverse reaction to antitumor drug | |
| EP3124486A4 (en) | Substituted nitrogen-containing heterocyclic derivatives, pharmaceutical compositions comprising the same and applications of antitumor thereof | |
| EP3031449A4 (en) | Entecavir microspheres and pharmaceutical composition for parenteral administration containing same | |
| EP3290037A4 (en) | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | |
| MY188946A (en) | 7-(morpholinyl)-2-(n-piperazinyl methyl thieno [2, 3-c] pyridine derivatives as anticancer drugs | |
| HUE065010T2 (hu) | Gyógyszerként alkalmas benzazepin származékok | |
| EP3328411A4 (en) | RETARD AGGREGATE FORMULATIONS FOR GLAUCOMA | |
| EP2958594A4 (en) | Pharmaceutical composition for enhanced transmucosal administration of benzodiazepines | |
| EP3126356A4 (en) | Sigma-2 receptor ligand drug conjugates as antitumor compounds, methods of synthesis and uses thereof | |
| IL256705A (en) | History of pyridine and pirazine, their preparation and pharmaceutical preparations containing them | |
| PL401345A1 (pl) | Pochodne kamptotecyny, sposób ich otrzymywania i zastosowanie |